Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02179008 · ClinicalTrials.gov registry record · Phase 2
Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Santen.
- Completed
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
NCT02179008: Completed Phase 2 study, sponsored by Santen.
NCT02179008 is a Phase 2 study that has completed, run by Santen. The registered enrollment target is 184 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02179008, a Phase 2 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of five concentrations of DE-117 ophthalmic solution.
Primary Outcome
Intraocular pressure (mmHg) measurements will be collected using Goldmann applanation tonometry
Interventions
- DRUG DE-117 Low Dose ophthalmic solution
- DRUG DE-117 Low/Middle Dose ophthalmic solution
- DRUG DE-117 Middle Dose ophthalmic solution
- DRUG DE-117 Middle/High Dose ophthalmic solution
- DRUG DE-117 High Dose ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT02179008 record still lists
NCT02179008 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% higher).
The record links to 0 conditions, and to 5 interventions - of which DE-117 Low Dose ophthalmic solution is the first listed.
NCT02179008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02179008 about?
NCT02179008 is a clinical study titled "Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension". The purpose of this study is to investigate the safety and efficacy of five concentrations of DE-117 ophthalmic solution.
What is the current status of trial NCT02179008?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2014-06. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02179008?
The interventions under investigation include: DE-117 Low Dose ophthalmic solution (DRUG), DE-117 Low/Middle Dose ophthalmic solution (DRUG), DE-117 Middle Dose ophthalmic solution (DRUG), DE-117 Middle/High Dose ophthalmic solution (DRUG), DE-117 High Dose ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02179008?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02179008's enrollment target sits among peer trials
184 360th of 2000 higher than 1,638 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia